Skip to content

Abstract B061: Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells

Sep 2026 · Cancer Research · 0 citations

TL;DR

The findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition, and may represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, mainly due to limited therapeutic options, late diagnosis and rapid development of drug resistance. Recently, multiple pan- and mutation-selective KRAS inhibitors have been developed, showing significant survival benefit, including the KRASG12D inhibitor MRTX1133. Unfortunately, as observed with the KRASG12C inhibitors, resistance mechanisms often limit its long-term efficacy. Epigenetic remodeling, particularly via the histone methyltransferase enhancer of zeste homolog 2 (EZH2), has been implicated in cell plasticity and therapy resistance by repressing epithelial programs while inducing more aggressive cellular states. Here, we investigated the mechanisms driving resistance to MRTX1133 in PDAC. We established three MRTX1133-resistant (MRTX1133_R) cell lines through chronic exposure to escalating drug concentrations. After, we employed bulk RNA sequencing followed by gene set enrichment analysis to reveal alterations between MRTX1133_R and parental counterparts. We then performed multiple functional assays to characterize the mechanisms driving the resistant phenotype. Additionally, we stained human samples from a tissue microarray by immunohistochemistry to assess the translation of our findings. We found that KRAS inhibitor-resistant cells exhibited profound molecular rearrangements, including loss of epithelial markers (E-cadherin, Claudin-1), and increased expression of mesenchymal players (N-cadherin, Slug), concomitantly with enhanced PI3K-mTOR pathway activity. RNA sequencing analysis revealed enhanced cellular plasticity and enrichment of neuroendocrine (NE) and EZH2-associated transcriptional programs, marked by higher expression of several NE markers, including ASCL1, CHGA, NKX2-2, and PAX6. Importantly, treatment with an EZH2 inhibitor – Tazemetostat – markedly reduced the proliferation of MRTX1133_R cells, abolished H3K27me3 protein levels and decreased expression of NE markers. Combined treatment of Tazemetostat and MRTX1133 re-sensitized resistant cells, leading to a significant reduction in cell viability alongside cell death induction. Remarkably, Tazemetostat synergized with the dual mTOR/PI3K inhibitor Dactolisib to significantly reduce cell viability, providing an alternative therapeutic option. Importantly, in human samples, high percentage of EZH2+ cells significantly associated with advanced stages, lymph node-positive cases, as well as recurrence at distant sites, particularly in the lung. Overall, our findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition. Targeting EZH2 may therefore represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients. Gonçalo Outeiro-Pinho, Aref Hosseini, Maciej Garczyk, Stephan von. Gunten, Beat Gloor, Anna Silvia. Wenning, Hannah L. Williams, Martin Wartenberg, Georgia Konstantinidou. Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B061.

View source

Similar papers

Sep 2026

Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer

This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.

J. Romero, Yi-Fan Wang, Edward Shanbedi et al. · 0 citations
Sep 2026

Abstract B064: xCT promotes SMAD signaling to induce gemcitabine resistance in KRAS-mutated pancreatic cancer

KRAS mutations are highly prevalent in pancreatic ductal adenocarcinoma (PDAC), leading to poor prognosis. Although gemcitabine is mainly utilized as the first-line treatment, patients with PDAC often develop resistance. However, the underlying mechanism of gemcitabine resistance in KRAS-mutant PDAC remains unclear....

J. S. Park · 0 citations
Sep 2026

Abstract B063: Exploring combination therapies to overcome RAS inhibitor resistance in pancreatic cancer

RASi-resistant in vitro and in vivo models of murine and human PDAC are generated to inform the development of more effective combination strategies for PDAC by defining resistance mechanisms and revealing therapeutic vulnerabilities, with potential implications for translational efforts in a disease with significant u...

Vasiliki I. Pantazopoulou, Casie S. Kubota, W. Jung et al. · 0 citations
Sep 2026

Abstract B060: From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer

Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...

T. McFall, Daniel Dorbin, Julia R. Herrera et al. · 0 citations
Sep 2026

Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.

Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al. · 0 citations
Sep 2026

Abstract PR012: Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer

This study defines adaptive resistance mechanisms to KRAS-targeted therapy in PDAC, revealing both cell-state-dependent RTK rewiring and a conserved SFK adaptive signaling axis and provides a mechanistic rationale for either KRAS/pan-RAS or pan-RAS/SFK co-inhibition as strategies to improve responses to KRAS-targeted t...

Qing-Xiang Lin, Bo-Kai Song, C. Sander et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.